explore -WSS

explore

author：explore 2025-09-28 18:30:40 - browse：52781

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Q&A: Jennifer Adair on making gene therapy available globally

WSS

Many breast cancer patients receive more radiation than needed

It was time to plan for my old age. If only I could stop crying

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Close Medicare's dangerous gaps in addiction treatment coverage

Google's generative AI to analyze medical images — and talk to docs

Feed a cold, starve a fever? Here’s what science says

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Sports medicine is finally prioritizing gender equality

Slovenia has suffered its worst

Guidelines to prevent youth baseball injuries need more muscle

Trump used to be more articulate. What could explain the change?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Paxlovid rebound happens. Why and to whom are still a mystery

How to save PrEP access — and even expand it

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Apple is now the first public company to be valued at $3 trillion

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

hotspot

Judge in Trump's classified documents case questions use of out

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

H5N1 bird flu virus started spreading in cows in Texas in December

Why rehabilitation engineers need to center patients in their research

UnitedHealth financials solid despite Change Healthcare cyberattack

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

knowledge

explore

leisure time

Wikipedia